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ABSTRACT  25 
 26 
Background and Objectives: In a previous genome-wide screening, we identified 27 
hypermethylated CpG islands around glutamate decarboxylase 1 (GAD1) in lung 28 
adenocarcinoma (LADC). In this study, we aimed to investigate the methylation and expression 29 
status of GAD1 and its prognostic value in patients with LADC. 30 
 31 
Methods: GAD1 methylation and mRNA expression status were analyzed using 33 tumorous 32 
and paired non-tumorous LADC samples and publicly available datasets. The prognostic value 33 
of GAD1 overexpression was investigated using publicly available datasets of mRNA levels and 34 
162 cases of LADC by immunohistochemistry. 35 
 36 
Results: The methylation and mRNA expression levels of GAD1, each having a positive 37 
correlation, were significantly higher in LADC tumors than in paired non-tumorous tissues. 38 
LADC patients with higher GAD1 mRNA expression showed significantly poorer prognosis for 39 
overall survival in publicly available datasets. Higher immunoreactivity of GAD1 was 40 
significantly associated with the pathological stage, pleural invasion, lymph vessel invasion, and 41 
poorer prognosis for cancer-specific and disease-free survival. Multivariate analysis revealed 42 
that GAD1 protein overexpression is an independent prognosticator for disease-free survival. 43 
 44 
Conclusions: GAD1 mRNA and protein expression levels were significant prognostic factors in 45 
LADC, suggesting that they might be useful biomarkers to stratify patients with worse clinical 46 
outcome after resection. 47 
 48 
Keywords: GAD1, lung adenocarcinoma, expression, prognosis, DNA methylation 49 
 50 
3 
 
1. INTRODUCTION 51 
Lung adenocarcinoma (LADC) is the predominant histological subtype of lung cancer and has 52 
the highest mortality rate worldwide [1, 2]. Although progress in the treatment of LADC has 53 
improved short-term survival, the impacts on long-term survival remain modest [3]. Therefore, 54 
a better understanding of the mechanisms of LADC tumor progression is needed and useful 55 
prognostic molecular markers for accurately predicting the clinical outcomes of LADC are of 56 
great clinical significance. 57 
To identify genes in the tumor that are specifically methylated at an early-stage of LADC, 58 
we had previously performed a genome-wide screening of aberrantly methylated CpG islands 59 
(CGIs) using paired tumorous and non-tumorous tissues of early-stage LADC, and identified 60 
TRIM58 as a novel candidate tumor-suppressor gene for this disease [4]. Through this screening, 61 
the glutamate decarboxylase 1 gene (GAD1) was found to be nearby hypermethylated CGIs in 62 
LADC. Because paradoxical hypermethylation-associated overexpression of GAD1 was 63 
reported recently in colorectal and liver cancers [5] and GAD1 overexpression has been reported 64 
in various neoplastic tissues, such as oral, nasopharyngeal, colorectal, liver, and gastric cancers 65 
[5-9], we focused on GAD1 as a potential LADC-related gene in the present study. Moreover, 66 
the methylation and expression status and clinicopathological significance of GAD1 in LADC 67 
tumorigenesis have also not been examined previously.  68 
Therefore, in the present study, we investigated the DNA methylation and mRNA and 69 
protein expression status of GAD1 in resected LADC tumors. Moreover, we assessed the 70 
prognostic significance of GAD1 expression in LADC using our tumor panel and publicly 71 
available datasets.  72 
 73 
2. MATERIALS AND METHODS 74 
2.1. Selection of candidate CGI 75 
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Previously obtained Human Methylation 450K array-based methylation screening data of 12 76 
paired tumorous/non-tumorous stage-I LADC sample sets from patients (6 smokers and 6 never-77 
smokers) who underwent surgery at Tokushima University Hospital (Tokushima, Japan) 78 
between April 1999 and March 2015 were reevaluated (Supplementary Table S1) [4]. 79 
 80 
2.2. Patients and tissue samples 81 
We included tumors and non-tumorous tissues of LADC that were surgically resected at 82 
Tokushima University Hospital between April 1999 and November 2013 for additional analyses. 83 
No patients had been administered preoperative radiation, chemotherapy, or immunotherapy. 84 
For pyrosequencing-based methylation analysis and real-time PCR-based expression analysis, 85 
33 LADC samples were used (Supplementary Table S2). For immunohistochemical staining, 86 
162 LADC samples were used (Supplementary Table S3). The mean follow-up duration for the 87 
162 patients with LADC was 48 months (range, 0.6–147 months), with 45 recurrences (27.8%) 88 
and 34 deaths (21.0%) among the patients. Tumor staging was determined based on the seventh 89 
tumor-node-metastasis (TNM) classification for lung cancer [10]. The tumors were classified 90 
according to the predominant histological subtype, as proposed by the 2015 WHO classification 91 
[11]. 92 
This study was performed in accordance with the principles outlined in the Declaration of 93 
Helsinki. The ethics committee of Tokushima University Hospital approved the study (approval 94 
number 3048), and formal written consent was obtained from all patients or their 95 
representatives. 96 
 97 
2.3. DNA and RNA preparation and bisulfite conversion of genomic DNA 98 
DNA and RNA were extracted using standard methods. Bisulfite conversion of DNA was 99 
conducted using the EpiTect Bisulfite Kit (QIAGEN GmbH, Hilden, Germany) following the 100 
manufacturer’s instructions. 101 
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 102 
2.4. Bisulfite pyrosequencing 103 
Bisulfite-treated genomic DNA was amplified using a set of primers designed with PyroMark 104 
Assay Design Software version 2.0.01.15 (QIAGEN GmbH, Supplementary Table S4). The 105 
target region for sequencing began 10 nucleotides (nt) before and ended 26 nt after cg15126544. 106 
PCR product pyrosequencing and methylation quantification were performed with sequencing 107 
primers using the PyroMark 24 Pyrosequencing System, version 2.0.6 (QIAGEN GmbH), 108 
according to the manufacturer’s instructions.  109 
 110 
2.5. Real-time quantitative reverse-transcription polymerase chain reaction (rqRT-PCR) 111 
Complementary DNA was generated from isolated total RNA using the PrimeScript II 1st strand 112 
cDNA Synthesis Kit (TaKaRa, Shiga, Japan). rqRT-PCR was performed using KAPA PROBE 113 
FAST qPCR Kits (Kapa Biosystems, Wilmington, MA, USA) and TaqMan Gene Expression 114 
Assays (Thermo Fisher Scientific, Waltham, MA, USA; Supplementary Table S4) according to 115 
the manufacturers’ instructions. GAPDH mRNA levels were used as internal controls for 116 
normalization. Relative expression of GAD1 mRNA was calculated using Human Lung Total 117 
RNA (TaKaRa) as a normal lung control. 118 
 119 
2.6. Data mining in bioinformatics 120 
Available RNA sequencing data (IlluminaHiSeq_RNASeqV2 Level 3) containing 488 tumor 121 
and 58 non-tumor samples and Infinium Human Methylation 450K data (Level 3) containing 122 
473 tumor and 32 non-tumorous samples of LADC cases with clinical annotations were 123 
downloaded from The Cancer Genome Atlas (TCGA) Research Network 124 
(http://cancergenome.nih.gov). mRNA expression data and DNA methylation data were 125 
available for 36 and 29 paired tumorous/non-tumorous sample sets, respectively; both types of 126 
data were available for 18 sets. Tumorous samples with mRNA expression data and survival 127 
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data were available for 423 cases. Survival analyses were conducted on patients with 128 
normalized mRNA expression and overall survival (OS) profiles. Patients were divided into 129 
low- and high-expression groups according to the median GAD1 mRNA expression value. 130 
 Kaplan-Meier Plotter (KM plotter, http://kmplot.com/analysis/), a publicly available online 131 
database of published microarray datasets for primary tumors with clinical information [12], 132 
was also used to generate OS curves in 9 studies from Gene Expression Omnibus (GEO, 133 
https://www.ncbi.nlm.nih.gov/geo/, Supplementary Table S5) by setting the auto-selected best 134 
value of GAD1 mRNA expression as the cutoff. All other parameters were left at default 135 
settings.  136 
 137 
2.7. Immunohistochemical staining 138 
Paraffin sections (4 µm thick) were subjected to immunohistochemical staining using the 139 
Envision system (ChemMate Envision kit; Dako, Glostrup, Denmark) according to the 140 
manufacturer’s instructions. Antigen retrieval was performed by heating the dewaxed and 141 
dehydrated sections in Dako Real Target Retrieval Solution, pH 9 (Dako), using a 2100 retriever 142 
(Aptum Biologics, Ltd., Southampton, UK). A mouse anti-GAD67 monoclonal antibody 143 
(Sigma-Aldrich, St. Louis, MO, USA; G5419), diluted to 1:200 with antibody diluents (Dako), 144 
was used as the primary antibody. The proportion and intensity of GAD1 staining in the LADC 145 
samples were scored (Supplementary Table S6A) independently by two different researchers. 146 
 147 
2.8. Statistical analysis 148 
Student’s t-test or Fischer’s exact test was used for comparisons between two groups. The 149 
paired t-test was used for comparisons between paired samples. The relationship between 150 
continuous variables was investigated by calculating the Spearman’s correlation coefficient. For 151 
survival analysis, Kaplan–Meier survival curves were constructed for groups based on 152 
univariate predictors, and differences among groups were tested with the log-rank test. 153 
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Univariate and multivariate survival analyses were performed using the likelihood ratio test of 154 
the stratified Cox proportional hazard regression analysis. Differences were assessed using two-155 
sided tests and were considered significant at a P-value of < 0.05. Statistical analyses were 156 
performed using IBM SPSS version 24 (IBM Corporation, Armonk, NY, USA) or the Survival 157 
package for R (https://cran.r-project.org). 158 
 159 
3. RESULTS 160 
3.1. Methylation status of CGIs and each CpG site within CGIs around GAD1  161 
In a previous array-based, genome-wide methylation screening of 12 paired tumorous/non-162 
tumorous LADC sample sets [4], CGI-3 around GAD1 was ranked 14th as a hypermethylated 163 
CGI with a high P-value (Supplementary Table S1). Because hypermethylation-associated 164 
overexpression of GAD1 was reported in colorectal and liver cancers [5], we re-evaluated the 165 
results of the array-based methylation status of each CpG site within CGI-1–4 (Fig. 1A) around 166 
GAD1 (Fig. 1B). The methylation levels of all CpG sites determined by array-based analysis 167 
within CGI-3 and in tumors were significantly higher than those in paired non-tumorous tissues. 168 
Although the methylation levels in tumors were higher in CpG sites within CGI-3 than in those 169 
within CGI-4, the average β-value in non-tumor tissues was extremely and specifically low at 170 
cg15126544 and showed the largest difference of average β-value between tumors and non-171 
tumor tissues at this site (Fig. 1B and Supplementary Table S7), which is localized within the 172 
CCCTC-binding factor (CTCF)-binding site of GAD1. Similar results were observed in the 173 
Level 3 Infinium Human Methylation 450K data of 29 LADC tumors and paired non-tumor 174 
tissues from TCGA dataset (Supplementary Fig. S1). Because hypermethylation around this 175 
CTCF-binding site has been reported as a possible cause of GAD1 overexpression [5], we 176 
further assessed the methylation status of cg15126544 and GAD1 mRNA expression levels.  177 
 178 
3.2. Correlation between GAD1 expression and CGI methylation in LADC clinical cases 179 
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The DNA methylation status and mRNA expression status were investigated in our panel of 180 
LADC tumorous and paired non-tumorous tissues (Supplementary Table S2) using 181 
pyrosequence-based methylation assays and rqRT-PCR-based expression analysis, respectively. 182 
Of the 33 sample sets, 26 (78.8%) demonstrated significantly higher methylation levels in tumor 183 
samples than in non-tumorous tissues (Fig. 1C). In the same cases, the mean GAD1 mRNA 184 
expression levels in the tumors were significantly higher than those in the paired non-tumorous 185 
tissues (Fig. 1D). There was a slightly positive (ρ = 0.251) but significant correlation between 186 
methylation levels at cg15126544 and GAD1 mRNA expression (Fig. 1E). The LADC sample 187 
set containing 18-paired samples obtained from TCGA demonstrated similar results both in 188 
methylation levels at cg15126544 and GAD1 mRNA expression (Fig. 1F, 1G and 189 
Supplementary Fig. S1). A significant and highly positive correlation between them was also 190 
observed in TCGA dataset (ρ = 0.706, Fig. 1H). Because the gene expression status of cancer 191 
cells directly affects their phenotypes, including malignant features, we focused on GAD1 192 
expression in tumors to further assess its prognostic significance in patients with LADC. 193 
 194 
3.3. Association of GAD1 mRNA expression levels with prognosis in LADC tumors 195 
In our LADC cohort, a sufficient number of cases with high-quality RNA suitable for 196 
expression analysis was not available for survival analysis. Therefore, to test the association 197 
between GAD1 mRNA expression levels in tumors and patients’ prognosis, we first performed 198 
survival analysis of 423 patients with LADC using data obtained from TCGA dataset. The OS 199 
rate of patients with LADC with higher GAD1 mRNA expression in tumors was significantly 200 
poorer than that of patients with lower GAD1 mRNA expression in tumors (Fig. 2A). Univariate 201 
Cox regression analysis using data obtained from TCGA dataset confirmed that high GAD1 202 
mRNA expression was associated with a worse prognostic significance for OS (Table 1). In 203 
multivariate Cox regression analysis, high GAD1 mRNA expression was also significantly 204 
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associated with a poorer OS rate, suggesting that GAD1 mRNA expression is an independent 205 
prognostic factor for OS (P = 0.036, Table 1).  206 
To validate this result, we performed survival analysis by drawing Kaplan-Meier survival 207 
curves using KM plotter (Fig. 2B). A total of 9 studies from the GEO dataset were included 208 
(Supplementary Table S5). In a total of 720 patients with LADC from 9 cohorts, high GAD1 209 
mRNA expression also significantly correlated with worse OS. In subgroup analysis of OS 210 
using datasets of KM plotter, heterogeneous results were obtained among different cohorts. 211 
Larger cohorts such as GSE31210 and GSE50081 consistently showed that higher GAD1 212 
mRNA expression was a poor prognostic factor, whereas cohorts with a smaller number of cases 213 
showed varying results (Supplementary Fig. S2). The results of univariate Cox regression 214 
analysis confirmed these results (Fig. 2C). 215 
 216 
3.4. Immunohistochemical staining pattern of GAD1 and its association with prognosis in 217 
LADC tumors 218 
To further validate the prognostic significance of GAD1 expression status, we further examined 219 
the correlation between GAD1 protein expression and clinicopathological features including 220 
prognosis in patients with LADC. We performed immunohistochemical staining of GAD1 in 221 
tissue samples from our cohort of 162 patients with LADC (Supplementary Table S3). 222 
Cytoplasmic GAD1 staining was observed in LADC tumor cells with higher mRNA expression, 223 
whereas nearly no staining was observed in normal lung epithelial cells and either tumorous or 224 
non-tumorous epithelial cells in LADC with lower mRNA expression (Fig. 3A). According to 225 
the staining score (Supplementary Table S6B), 112 patients (69.1%) were classified into the 226 
group with tumors showing GAD1 protein overexpression (positive GAD1 immunoreactivity). 227 
Among the various clinicopathological factors, the pathological stage, pleural invasion, and 228 
lymph vessel invasion were identified as factors significantly and positively associated with 229 
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positive GAD1 immunoreactivity (Table 2). Lymph node metastasis also tended to be more 230 
frequently observed in the positive GAD1 immunoreactivity group. 231 
According to the GAD1 protein expression status of LADC tumors, Kaplan-Meier curves 232 
of estimated OS, disease-free survival (DFS), and cancer-specific survival (CSS) were 233 
generated. Patients with GAD1 protein-overexpressing tumors showed significantly poorer DFS 234 
(P < 0.001, log-rank test) and CSS (P = 0.031, log-rank test) than those without GAD1 protein 235 
overexpressing tumors. Patients with GAD1 protein-overexpressing tumors tended to show 236 
poorer OS, although the difference between groups was not significant (Fig. 3B). Univariate 237 
Cox regression analysis confirmed that positive GAD1 immunoreactivity was significantly 238 
associated with a worse prognostic significance for DFS (Table 3). Multivariate Cox regression 239 
analysis in 162 patients revealed that GAD1 immunoreactivity was an independent prognostic 240 
factor for DFS (P = 0.011, hazard ratio = 6.424, Table 3), but not for OS and CSS 241 
(Supplementary Table S8 and S9).  242 
 243 
4. DISCUSSION 244 
In the present study, we focused on GAD1 as a hypermethylated gene at specific CpG sites in 245 
LADC tumors and demonstrated its overexpression in tumor-specific and methylation level-246 
associated manners in LADC. We also demonstrated the prognostic significance of GAD1 247 
mRNA and protein expression levels in resected LADC tumors using various independent 248 
publicly available datasets and our cohort, respectively. Our study suggested that GAD1 249 
overexpression may be a useful biomarker for predicting the prognosis of patients with LADC. 250 
GAD1 is known to catalyze the production of γ-aminobutyric acid (GABA) from L-251 
glutamic acid, the principal inhibitory neurotransmitter in the brain [13, 14]. GAD1 252 
overexpression has been reported in various neoplastic tissues, but not in LADC. Moreover, the 253 
associations between clinicopathological characteristics and GAD1 expression have not been 254 
well-established. The most striking finding in this study is the prognostic significance of GAD1 255 
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mRNA and protein expression in patients with LADC. Although a sufficient number of RNA 256 
samples suitable for expression analysis was not available in our cohort for survival analyses, 257 
we used various publicly available data and demonstrated that GAD1 mRNA overexpression in 258 
tumors was significantly associated with poor prognosis (OS) in independent TCGA and GEO 259 
datasets of LADC cases. In immunohistochemical analysis using our cohort, a positive 260 
cytoplasmic GAD1 staining pattern in tumor cells was significantly associated with poor 261 
prognosis, particularly DFS but not OS, in patients with LADC. Although the difference in the 262 
association between GAD1 expression and OS among datasets remains unclear, it may be 263 
explained by (1) variations in GAD1 mRNA and protein expression, (2) the smaller size of the 264 
cohort for immunohistochemical analysis compared to those of cohorts used for mRNA analysis 265 
used in our study, and (3) variations in GAD1 expression level and/or pattern among different 266 
ethnicities. 267 
Our study also demonstrated that GAD1 protein expression in LADC was significantly 268 
associated with pleural invasion and lymph vessel invasion. These findings suggest that GAD1 269 
overexpression might be closely associated with cellular invasion. This hypothesis is supported 270 
by previous reports of another cancers. Kimura et al. [6] demonstrated that GAD1 promotes the 271 
cancer cell invasion and metastasis of oral cancer by inducing the nuclear translocation of β-272 
catenin and secretion of MMP7 [15-20], although the regulatory mechanisms of GAD1 in β-273 
catenin translocation remain unclear. In a brain metastasis model, it was reported that the 274 
metastatic activity of tumor cells depends on the GAD1-GABA synthesis pathway [21]. Further 275 
studies are needed to clarify the tumor-promoting activity of overexpressed GAD1. 276 
Recently, Yan et al. [5] reported hypermethylation-associated GAD1 overexpression in 277 
colorectal and liver cancers and found that this paradoxical effect was caused by the 278 
hypermethylation of the CTCF-binding site within GAD1, which may prevent CTCF binding, 279 
inhibit CTCF-mediated repressive Polycomb repressive complex 2 (PRC2) complex recruitment 280 
to the GAD1 promoter, inhibit PRC2-induced trimethylation of histone H3 lysine 27 281 
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(H3K27m3), and eliminate the blocking activity H3K27m3 for GAD1 transcription [22, 23]. 282 
These observations are contradictory to the well-established paradigm that promoter DNA 283 
methylation represses transcription by inhibiting transcription factor binding and/or chromatin 284 
structure modification [24-26]. In this study, we also detected hypermethylation at cg15126544 285 
within the CTCF-binding site in LADC tumors, and tumor-specific GAD1 overexpression was 286 
positively associated with hypermethylation at cg15126544 in our cohort and the TCGA dataset. 287 
Therefore, methylation of CTCF-binding sites may regulate GAD1 expression in LADC as well. 288 
However, it remains unknown whether the methylation of CGI or each CpG site around GAD1, 289 
particularly cg15126544, is the only mechanism underlying the regulation of its transcription. 290 
Interestingly, in brain metastatic tumor cells, it was reported that the downregulation of the 291 
DNA methyltransferase DNMT1 induced by the brain microenvironment-derived clusterin 292 
resulted in decreased GAD1 promoter methylation and subsequent upregulation of GAD1 293 
expression [21]. Therefore, even the effect of methylation levels of CpG sites around GAD1 on 294 
its expression level may vary under different conditions or in different cell lineages. Indeed, 295 
MethSurv, a web tool for multivariable survival analysis using DNA methylation data obtained 296 
from TCGA datasets (https://biit.cs.ut.ee/methsurv/), failed to show the prognostic significance 297 
of CpG sites around GAD1, including cg15126544 for OS (data not shown). Therefore, the 298 
methylation status of some CpG sites around GAD1 may contribute to its gene expression at 299 
some stages of LADC development, but not to the progression of this tumor. The GAD1 mRNA 300 
expression level data in normal lung tissues available in public databases, such as the NIH 301 
Genotype-Tissue Expression Project (https://www.gtexportal.org/), as well as our 302 
immunohistochemical staining results revealed no or low GAD1 expression in normal lung 303 
tissue, suggesting that GAD1 is specifically expressed in tumor cells and contributes to the 304 
progression of tumors in LADC. Because the gene expression status appears to more directly 305 
contribute to the establishment of clinicopathological phenotypes in tumor cells, it is necessary 306 
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to investigate the detailed regulatory mechanisms of GAD1 expression in LADC cells at each 307 
developmental stage of the tumor.  308 
There are some limitations to this study. First, we demonstrated the prognostic impact of 309 
GAD1 mRNA and protein statuses mainly in Caucasian and Japanese (Asian) populations, 310 
respectively, but no data are available to directly compare GAD1 mRNA and protein expression 311 
levels among different ethnicities. Because it has been reported that the frequency of acquired 312 
alterations, such as epidermal growth factor receptor mutation, in lung tumors can vary across 313 
different ethnicities [27-29], it is possible that the GAD1 expression pattern and/or levels differ 314 
between Caucasian and Asian populations. However, the prognostic significance of the GAD1 315 
mRNA expression status in Japanese cases with LADC was demonstrated by GSE31210 in 316 
GEO datasets (Fig. 2C and Supplementary Fig. S2). Meta-analysis using 9 GEO datasets, 317 
including GSE31210 and 8 other studies from western countries (Supplementary Table S5) also 318 
revealed the prognostic significance of the GAD1 mRNA expression status (Fig. 2C), 319 
suggesting that GAD1 overexpression is a common prognostic factor in various populations. 320 
Second, our patient cohort was relatively small even for immunohistochemical analysis, and a 321 
sufficient number of samples was not available for mRNA expression analysis to perform 322 
survival analysis. Prospective multi-institutional studies are needed to further validate the 323 
prognostic value of GAD1 overexpression in patients with LADC.  324 
 325 
5. CONCLUSION 326 
GAD1 overexpression appears to be a significant and independent prognostic indicator in 327 
patients with resected LADC at both the mRNA and protein levels. This information may be 328 
helpful for identifying patients at high risk of recurrence and overall survival after tumor 329 
resection of LADC.  330 
  331 
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Table 1. Cox proportional hazard regression analysis of overall survival in 400 patients with LADC in TCGA dataset 436 
 437 
 
 
 
Factor (number) 
Univariate 
 
Multivariate 
Hazard ratio 
95% confidence 
interval 
P-value 
 
Hazard ratio 
95% confidence 
interval 
P-value 
Sex 
   Male (n = 184) 
vs. Female (n = 216) 
1.048 0.704 – 1.560 0.818 
 
1.087 0.705 – 1.675 0.706 
Age (years) 
   >67 (n = 210) 
vs. ≤67 (n = 190) 
1.348 0.897 – 2.025 0.151 
 
1.639 1.079 – 2.490 0.021 
Smoking history 
   Positive (n = 339) 
vs. Negative (n = 61) 
1.069 0.569 – 2.006 0.836 
 
1.521 0.766 – 3.020 0.230 
Pathological stage 
   II, III, IV (n = 184)    
   vs. I (n=216) 
2.620 1.725 – 3.979 6.21E-6 
 
- - - 
Tumor size  
   pT2-4 (n = 272) 
vs. pT1 (n = 128) 
1.631 0.978 – 2.720 0.0609 
 
1.565 0.922 – 2.658 0.097 
N stage (pN) 
   pN1-3 (n = 136) 
vs. pN0 (n = 264) 
2.475 1.662 – 3.688 8.32E-6 
 
2.487 1.649 – 3.750 1.38E-5 
M stage (pM) 
   pM1 (n 19) 
   vs. pM0 (n = 381) 
1.539 0.773 - 3.066 0.220 
 
1.528 0.752 – 3.103 0.241 
GAD1 mRNA expression 
   High (n = 217) 
vs. Low (n = 183) 
1.749 1.165 – 2.626 6.97E-3 
 
1.573 1.029 – 2.404 0.036 
Statistically significant values are in boldface type. 438 
The analysis was performed in 400 patients with complete clinical information in the TCGA dataset. 439 
The population was divided using the auto-selected best value of GAD1 mRNA expression as the cutoff. 440 
  441 
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Table 2. Correlation between GAD1 immunoreactivity and clinicopathological factors in 162 patients with LADC  442 
 443 
Factor 
GAD1 immunoreactivity (n = 162) 
P-valuea 
Negative (n = 50) Positive (n = 112) 
Male / Female 26 / 24 55 / 57 0.865 
Ageb 69.0 ± 9.6 67.4 ± 9.0 0.386 
Smoking historyb, c (+/-)  22 / 27 55 / 56 0.603 
Brinkman indexb, c 406.5 ± 536.4 485.0 ± 622.7 0.461 
Tumor sizeb, c 23.5 ± 14.3 26.1 ± 13.4 0.226 
pStage (I/II+III) 39 / 11 65 / 47 0.021 
Lymph node metastasis (+/-) 8 / 42 36 / 76 0.054 
Pleural invasionc (+/-) 5 / 40 35 / 72 0.005 
Vascular invasionc (+/-) 5 / 40 22 / 79 0.284 
Lymph vessel invasionc (+/-) 6 / 39 31 / 66 0.023 
EGFR mutationc (+/-) 10/ 6 30/ 29 0.573 
Predominant histologic subtype 
(lepidic / papillary / acinar/ solid/ 
enteric) 
23 / 18 / 4 / 4 / 1 36 / 47 / 24 / 5 / 0 0.068 
aP-values were calculated using Fischer's exact test for gender, smoking history, lymph node metastasis, pleural invasion, lymph 444 
vessel invasion, and vascular invasion, EGFR mutation, and using Student’s t-test for age, Brinkman index, and tumor size and 445 
using χ 2 test for trend for predominant histologic subtype. Statistically significant values (P < 0.05) are in boldface type. 446 
bAge, Brinkman index, and tumor size are expressed as the mean ± standard deviation. 447 
cData of these factors were not available for all patients. 448 
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Table 3. Cox proportional hazard regression analysis for disease-free survival in 162 patients with LADC 450 
 451 
Factor 
Univariate  Multivariate 
Hazard 
ratio 
95% confidence 
interval 
P-value 
 Hazard 
ratio 
95% confidence 
interval 
P-value 
Sex 
   Male (n=81)  
vs. Female (n=81) 
1.202 0.666 - 2.170 0.541 
 
2.459 0.520 - 11.624 0.256 
Age (years) 
   >67 (n=87) 
vs. ≤67 (n=75) 
1.048 0.582 - 1.887 0.875 
 
0.995 0.515 - 1.922 0.988 
Smoking historya 
   Positive (n=77) 
vs. Negative (n=83) 
1.302 0.724 - 2.344 0.378 
 
0.324 0.068 - 1.546 0.158 
Pathological stage 
II, III (n=58)    
vs. I (n=104) 
7.466 3.769 - 14.789 < 0.001 
 
- - - 
Tumor sizea 
   pT2-4 (n=39) 
vs. pT1 (n=115) 
2.309 1.241 - 4.296 0.008 
 
2.033 0.961 - 4.303 0.070 
N stage (pN) 
   pN1-3 (n=44) 
vs. pN0 (n=118) 
7.100 3.837 - 13.140 < 0.001 
 
2.507 1.057 - 5.949 0.037 
Pleural invasiona  
   Positive (n=40) 
vs. Negative (n=112) 
4.926 2.637 - 9.202 < 0.001 
 
2.091 0.977 - 4.478 0.058 
Vascular invasiona  
   Positive (n=27) 
vs. Negative (n=119) 
4.706 2.529 – 8.757 < 0.001 
 
1.139 0.389 - 3.341 0.812 
Lymph vessel invasiona  
   Positive (n=37) 
vs. Negative (n=105) 
5.346 2.809 - 10.175 < 0.001 
 
1.355 0.478 - 3.847 0.568 
Adjuvant chemotherapya 
   With (n=47) 
   vs. Without (n=106) 
2.972 1.614 - 5.470 < 0.001 
 
- - - 
EGFR mutationa 
   Negative (n=35) 
   vs. Positive (n=40) 
1.285 0.678 - 2.433 0.442 
 
- - - 
Predominant subtype  
   Non-lepidic (n=103) 
   vs. Lepidic (n=59) 
6.711 2.392- 18.868 < 0.001 
 
2.725 0.861 - 8.621 0.088 
GAD1 immunoreactivity 
   Positive (n=112) 
vs. Negative (n=50) 
9.341 2.248 - 38.824 0.002 
 
6.424 1.522 - 27.108 0.011 
Statistically significant values are in boldface type. 452 
a
Data of these factors were not available for all patients. 453 
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Supplementary Table S1. The top 14 CpG islands significantly hypermethylated in tumorous tissues of 12 stage-I LADC cases4 455 
 456 
No. CpG island Adjusted P-value
a
 β-difference
b
 Gene name 
1 chr7:153583317-153585666 0.000495704 0.277562652 DPP6 
2 chr19:52390841-52391368 0.000671077 0.291495741 ZNF577 
3 chr11:125774292-125774584 0.000839411 0.271871389 DDX25 
4 chr3:62355315-62355534 0.001348289 0.25890625 FEZF2 
5 chr1:156863415-156863711 0.001564128 0.369176667 PEAR1 
6 chr15:37390175-37390380 0.002225792 0.324917222 MEIS2 
7 chr1:248020330-248021252 0.00443318 0.270335 TRIM58 
8 chr12:103696090-103696418 0.006552561 0.318931667 C12orf42 
9 chr7:158110569-158110881 0.008975336 0.270233333 PTPRN2 
10 chr6:50810642-50810994 0.010799023 0.30752125 TFAP2B 
11 chr5:134363092-134365146 0.011483039 0.262798796 PITX1 
12 chr19:58545115-58545897 0.011599292 0.27722213 ZSCAN1 
13 chr6:50791110-50791573 0.012733507 0.331794167 TFAP2B 
14 chr2:171676552-171676980 0.017464759 0.251871944 GAD1 
The row corresponding to GAD1 is in boldface type. 457 
aDifferences between methylation levels (β-values) of CpG islands in tumors and paired non-tumorous tissues were assessed by 458 
paired t-test. P-values were adjusted with the Benjamini–Hochberg correction (false discovery rate, FDR). CpG islands were sorted 459 
by the adjusted P-value. 460 
bβ-differences (differential methylation levels) represent the average of [(β-value of tumorous tissue) - (β-value of paired non-461 
tumorous tissue)] in 12 stage-I LADC cases. 462 
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Supplementary Table S2. Clinicopathological characteristics of 33 patients with LADC analyzed by qPCR and pyrosequencing  464 
 465 
Characteristics Number 
Gender 
     Male 
     Female 
 
18 
15 
Age (years) 62.9 ± 9.6 
Stage  
     Ia, Ib 
     IIa, IIb 
     IIIa, IIIb 
 
16 
8 
9 
Smoking History 
     + 
     - 
 
15 
18 
Brinkman Index 616.7 ± 745.4 
Age and Brinkman index are expressed as the mean ± standard deviation. 466 
 467 
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Supplementary Table S3. Characteristics of 162 patients with LADC analyzed by immunohistochemistry 469 
 470 
Characteristics N = 162 (%) 
Gender 
     Male 
     Female 
 
81 (50.0%) 
81 (50.0%) 
Age (years) 67.0 ± 9.2 
Stage  
     Ia, Ib 
     IIa, IIb 
     IIIa, IIIb 
 
104 (64.2%) 
26 (16.0%) 
32 (19.8%) 
EGFR mutation 
    Positive 
     Negative 
    Unknown 
 
40 (24.7%) 
35 (21.6%) 
87 (53.7%) 
Predominant histologic subtype 
     lepidic 
     papillary  
     acinar 
     solid 
     enteric 
 
59 (36.4%) 
65 (40.1%) 
28 (17.3%) 
  9 (5.6%) 
  1 (0.6%) 
Adjuvant chemotherapy 
     With 
     Without 
     Unknown 
 
47 (29.0%) 
106 (65.4%) 
  9 (5.6%) 
Smoking History 
     + 
     - 
     Unknown 
 
78 (48.1%) 
82 (50.6%) 
2 (1.2%) 
Brinkman Index 461.0 ± 597.0 
Age and Brinkman index are expressed as the mean ± standard deviation.  471 
24 
 
Supplementary Table S4. List of primer sets used in qPCR and pyrosequencing 472 
 473 
  Gene/primer name   Sequence/ID 
 TaqMan gene expression assay 
  GAD1 FAM Hs01065893_m1 
  GAPDH FAM Hs02758991_g1 
       
 Pyrosequencing of GAD1 
  cg15126544 Forward 5'-TGGTTTTTAGGGGTTTTTTTTTTTGGA-3' 
  Reverse 5'-ACAAATACACCCCCTTTAATCTACTCTCC-3' 
  Sequence 5'-GTAGAAGAGGGAGGAA-3' 
 474 
 475 
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Supplementary Table S5. List of GEO data sets 477 
 478 
GEO accession Survival period Submission date 
Number of 
patients Country Race Platform 
GSE14814 
from date of random assignment to 
death from disease or treatment 
complication 
12-Feb-9 27 
Canada 
USA 
Germany 
NA HG-U133A, 
GSE19188 NA 25-Nov-9 41 Netherlands Mostly Caucasian HG-U133_Plus_2 
GSE3141 NA 16-Aug-5 58 USA NA HG-U133_Plus_2 
GSE50081 NA 21-Aug-13 127 Canada NA HG-U133_Plus_2 
GSE31908 NA 6-Sep-11 20 USA 
Mostly 
Caucasian 
HG-U133A HG-
U133B HG-
U133_Plus_2 
GSE37745 NA 3-May-12 106 Sweden NA HG-U133_Plus_2 
GSE29013 
from the date of surgery to death or 
the last follow-up contact. 
2-May-11 30 USA 
Mostly 
Caucasian 
HG-U133_Plus_2 
GSE30219 NA 26-Jun-11 85 
France 
USA 
NA HG-U133_Plus_2 
GSE31210 NA 4-Aug-11 226 Japan Asian HG-U133_Plus_2 
   
   
 479 
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Supplementary Table S6. Evaluation criteria for GAD1 immunohistochemistry 481 
 482 
A. Proportion and intensity scores for GAD1 staining in immunohistochemical analysis 483 
Proportion score (PS)  Intensity score (IS) 
Score Observation  Score Observation 
1 < 25%  0 None 
2 26 - 50%  1 Weak 
3 51 - 75%  2 Intermediate 
4 76% ≤  3 Strong 
 484 
B. Evaluation of GAD1 immunoreactivity using PS and IS 485 
GAD1 
immunoreactivity 
Sum of PS and IS Number of cases 
Negative 
1 0 
2 14 
3 10 
4 26 
Positive 
5 44 
6 43 
7 25 
The staining score is defined as the sum of the proportion and intensity scores.  486 
A staining score ≥ 5 indicated overexpression of the GAD1 protein (positive GAD1 immunoreactivity).  487 
  488 
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Supplementary Table S7. The methylation levels of each CpG site of GAD1 in tumorous and non-tumorous samples  489 
 490 
CpG site 
β-value (averagea)  β-value (SDb) 
P-valuec β-differenced 
Tumor Non-tumor  Tumor Non-tumor 
cg09404592 0.109475 0.0853917  0.04619235 0.02516931 0.1810443145  0.024083333 
cg03443455 0.462661667 0.3074692  0.09759064 0.04014665 0.0004807189  0.1551925 
cg00782607 0.106084167 0.0710583  0.04960498 0.03644913 0.0389929681  0.035025833 
cg13612847 0.133873333 0.1472975  0.03817365 0.03253079 0.0972520412  -0.013424167 
cg03448612 0.083106667 0.0758158  0.02049695 0.03057835 0.3611596712  0.007290833 
cg09742688 0.019295 0.014535  0.00964859 0.00580472 0.1767899083  0.00476 
cg23221504 0.100365 0.1095158  0.02678416 0.03834864 0.3202119878  -0.009150833 
cg00915206 0.067003333 0.0671983  0.01743706 0.03309326 0.9850457390  -0.000195 
cg11582100 0.05327 0.0542092  0.01019424 0.02677933 0.8871008599  -0.000939167 
cg15306595 0.0394325 0.0438158  0.01045799 0.01931569 0.4524979803  -0.004383333 
cg19538089 0.104192727 0.0801767  0.05266865 0.02819045 0.1330389745  0.024016061 
cg26391350 0.086990833 0.0757083  0.02871752 0.03569546 0.2703867579  0.0112825 
cg16911423 0.179124167 0.13477  0.05271661 0.02415412 0.0169907853  0.044354167 
cg01763173 0.085408333 0.0639708  0.03334425 0.02293707 0.0705795610  0.0214375 
cg11281641 0.154460833 0.0533167  0.0959479 0.02516992 0.0046353604  0.101144167 
cg07420274 0.536216667 0.3580283  0.06408349 0.05326207 0.0001252001  0.178188333 
cg01089249 0.529403333 0.2895042  0.06934644 0.02343744 0.0000006700  0.239899167 
cg01089319 0.505844167 0.256055  0.06506377 0.03497551 0.0000011299  0.249789167 
cg14005211 0.539773333 0.2738458  0.0827698 0.05432622 0.0000013853  0.2659275 
cg14486905 0.46974 0.2449983  0.12168293 0.04163571 0.0002223438  0.224741667 
cg09144707 0.494621667 0.2901625  0.10770392 0.03041366 0.0000452368  0.204459167 
cg02723395 0.411985 0.1740225  0.15358608 0.0351129 0.0005880955  0.2379625 
cg15126544 0.363693333 0.0397042  0.14160994 0.02161663 0.0000079194  0.323989167 
cg04105250 0.337811667 0.1510408  0.11281548 0.02977583 0.0001733147  0.186770833 
cg00729049 0.2934125 0.1690383  0.08912118 0.02842007 0.0014668716  0.124374167 
cg15753746 0.363454167 0.1337517  0.17759626 0.03602908 0.0009859990  0.2297025 
cg21535772 0.4300025 0.2728233  0.09775366 0.03462184 0.0004699895  0.157179167 
cg19846314 0.445076667 0.2232308  0.17797695 0.07571523 0.0024014465  0.221845833 
cg08863440 0.403660833 0.2232942  0.15063177 0.06307915 0.0033596932  0.180366667 
cg07620853 0.5666125 0.5479283  0.19697479 0.14942316 0.7081756486  0.018684167 
The row corresponding to cg15126544 is in boldface type. 491 
aThe average methylation level of 12 LADC samples. 492 
bThe standard deviation (SD) of methylation levels of 12 LADC samples. 493 
cDifferences between methylation levels (β-values) of CpG islands in tumors and paired non-tumorous tissues were assessed by paired 494 
t-test. 495 
dβ-differences (differential methylation levels) represent the average of [(β-value of tumorous tissue) - (β-value of paired non-tumorous 496 
tissue)] in 12 stage-I LADC cases.  497 
 498 
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Supplementary Table S8. Cox proportional hazard regression analysis of overall survival in 162 patients with LADC 500 
 501 
Factor 
Univariate  Multivariate 
Hazard 
ratio 
95% confidence 
interval 
P-value 
 Hazard 
ratio 
95% confidence 
interval 
P-value 
Sex 
   Male (n=81)  
vs. Female (n=81) 
3.219 1.452 - 7.138 0.004 
 
1.311 0.220 - 7.802 1.311 
Age (years) 
   >67 (n=87) 
vs. ≤67 (n=75) 
2.471 1.169 - 5.224 0.018 
 
2.562 1.073 - 6.120 0.034 
Smoking historya 
   Positive (n=77) 
vs. Negative (n=83) 
4.177 1.817 - 9.602 0.001 
 
2.166 0.341 - 13.759 0.413 
Pathological stage 
II, III (n=58)    
vs. I (n=104) 
4.328 1.999 - 9.372 < 0.001 
 
- - - 
Tumor sizea 
   pT2-4 (n=39) 
vs. pT1 (n=115) 
2.262 1.119 - 4.573 0.023 
 
2.466 1.116 - 5.447 0.026 
N stage (pN) 
   pN1-3 (n=44) 
vs. pN0 (n=118) 
3.577 1.789 - 7.151 < 0.001 
 
0.909 0.343 - 2.410 0.848 
Pleural invasiona  
   Positive (n=40) 
vs. Negative (n=112) 
2.051 0.987 - 4.264 0.054 
 
1.635 0.626 - 4.267 0.315 
Vascular invasiona  
   Positive (n=27) 
vs. Negative (n=119) 
2.735 1.284 – 5.826 0.009 
 
0.487 0.157 - 1.512 0.213 
Lymph vessel invasiona  
   Positive (n=37) 
vs. Negative (n=105) 
4.700 2.203 - 10.027 < 0.001 
 
3.897 1.311 - 11.580 0.014 
Adjuvant chemotherapya 
   With (n=47) 
   vs. Without (n=106) 
0.996 0.472 - 2.101 0.991 
 
- - - 
EGFR mutationa 
   Negative (n=35) 
   vs. Positive (n=40) 
2.882 1.151 - 2.564 0.024 
 
- - - 
Predominant subtype  
   Non-lepidic (n=103) 
   vs. Lepidic (n=59) 
3.311 1.156- 9.524 0.026 
 
2.841 0.590 - 13.699 0.193 
GAD1 immunoreactivity 
   Positive (n=112) 
vs. Negative (n=50) 
2.315 0.895 - 5.992 0.084 
 
1.216 0.366 - 4.042 0.750 
Statistically significant values are in boldface type. 502 
a
Data of these factors were not available for all patients. 503 
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Supplementary Table S9. Cox proportional hazard regression analysis of cancer-specific survival in 162 patients with LADC 505 
 506 
Factor 
Univariate  Multivariate 
Hazard 
ratio 
95% confidence 
interval 
P-value 
 Hazard 
ratio 
95% confidence 
interval 
P-value 
Sex 
   Male (n=81)  
vs. Female (n=81) 
1.945 0.827 - 4.576 0.127 
 
1.160 0.194 - 6.923 0.871 
Age (years) 
   >67 (n=87) 
vs. ≤67 (n=75) 
1.735 0.749 - 4.021 0.199 
 
1.932 0.748 - 4.987 0.173 
Smoking historya 
   Positive (n=77) 
vs. Negative (n=83) 
2.599 1.076 - 6.279 0.034 
 
1.398 0.221 - 8.839 0.722 
Pathological stage 
II, III (n=58)    
vs. I (n=104) 
7.706 2.606 - 22.791 < 0.001 
 
- - - 
Tumor sizea 
   pT2-4 (n=39) 
vs. pT1 (n=115) 
1.994 0.847 - 4.697 0.114 
 
1.867 0.733 - 4.758 0.191 
N stage (pN) 
   pN1-3 (n=44) 
vs. pN0 (n=118) 
6.066 2.488 - 14.789 < 0.001 
 
1.322 0.398 - 4.395 0.649 
Pleural invasiona 
   Positive (n=40) 
vs. Negative (n=112) 
2.331 0.957 - 5.677 0.063 
 
1.255 0.429 - 3.673 0.679 
Vascular invasiona 
   Positive (n=27) 
vs. Negative (n=119) 
4.089 1.697 – 9.854 0.002 
 
0.892 0.236 - 3.378 0.867 
Lymph vessel invasiona  
   Positive (n=37) 
vs. Negative (n=105) 
5.610 2.239 - 14.055 < 0.001 
 
2.654 0.703 - 10.022 0.150 
Adjuvant chemotherapya 
   With (n=47) 
   vs. Without (n=106) 
1.036 0.428 - 2.504 0.938 
 
- - - 
EGFR mutationa 
   Negative (n=35) 
   vs. Positive (n=40) 
3.165 1.188 - 8.403 0.021 
 
- - - 
Predominant subtype  
   Non-lepidic (n=103) 
   vs. Lepidic (n=59) 
9.804 1.311- 71.429 0.026 
 
3.378 0.392 - 29.411 0.268 
GAD1 immunoreactivity 
   Positive (n=112) 
vs. Negative (n=50) 
4.323 1.015 - 18.420 0.048 
 
3.400 0.415- 27.827 0.254 
Statistically significant values are in boldface type. 507 
a
Data of these factors were not available for all patients. 508 
 509 
  510 
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Figure Legends 511 
 512 
Figure 1. DNA methylation and mRNA expression status of GAD1 in patients with 513 
LADC.  514 
(A) A schematic diagram of the GAD1 gene structure with CGIs around GAD1. The 515 
arrow indicates the location of cg15126544.  516 
(B) The average β-value (methylation level) of each CpG site targeted in the array-based 517 
methylation experiment involving 12 LADC cases. *P < 0.05 vs. paired non-tumorous 518 
tissues.  519 
(C) Linear plots of the average DNA methylation values (percentages) of cg15126544 in 520 
33 LADC tumorous and paired non-tumorous tissues, as determined by quantitative 521 
pyrosequencing. Samples from the same patient are linked with straight lines. 522 
(D) Linear plots of expression levels of GAD1 mRNA relative to those of the control 523 
normal human lung in 33 LADC tumorous and paired non-tumorous tissues. Relative 524 
expression of GAD1 mRNA was calculated using Human Lung Total RNA as a normal 525 
control.  526 
(E) Correlation between the average methylation levels of cg15126544 (x-axis) and 527 
relative GAD1 mRNA expression levels (y-axis) in 33 LADC tumorous and paired non-528 
tumorous tissues.  529 
(F) Linear plots of the methylation levels (β-values) of cg15126544 determined through 530 
an array-based methylation experiment using HumanMethylation450K array in 18 531 
paired LADC tumor and non-tumorous tissue samples obtained from the TCGA dataset 532 
(http://cancergenome.nih.gov).  533 
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(G) Linear plots of mRNA expression of GAD1 determined by RNA sequencing and 534 
quantified by RNA-Seq by Expectation Maximization (RSEM) in 18 paired LADC 535 
tumor and non-tumorous tissue samples obtained from the TCGA dataset.  536 
(H) Correlation between the methylation levels (β-values) of cg15126544 (x-axis) and 537 
GAD1 mRNA expression levels (y-axis) in 18 paired LADC tumor and non-tumorous 538 
tissue samples obtained from the TCGA dataset. 539 
 540 
Figure 2. Publicly available datasets showing association between GAD1 mRNA 541 
expression status and prognosis in patients with LADC. 542 
(A) Kaplan-Meier curve for OS rate of 423 LADC patients according to GAD1 mRNA 543 
expression levels using data obtained from the TCGA dataset. P-values were calculated 544 
using the log-rank test. Statistically significant P-values are in boldface type. 545 
(B) Kaplan-Meier curve for OS rate of 720 LADC patients in cohorts GSE14814, 546 
GSE19188, GSE3141, GSE50081, GSE31908, GSE37745, GSE29013, GSE30219, and 547 
GSE31210 according to GAD1 mRNA expression levels obtained from the online 548 
survival analysis software, Kaplan–Meier plotter (KM plotter; http://www.kmplot.com). 549 
P-values were calculated using the log-rank test. Statistically significant P-values are in 550 
boldface type. 551 
(C) Subgroup analysis of KM plotter databases for GAD1 mRNA expression in LADC. 552 
Hazard ratios (HR, center of the box) and 95% confidence intervals (CI, horizontal line) 553 
were calculated with Cox's regression models. 554 
 555 
Figure 3. Association between GAD1 protein expression status and prognosis in 556 
patients with LADC.  557 
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(A) Representative images of immunohistochemically detected GAD1 protein in tumors 558 
and non-tumorous lesions of LADC samples and normal lung tissue. Scale bars, 200 559 
μm. The relative GAD1 mRNA expression level of each sample as determined by rqRT-560 
PCR is also shown.  561 
(B) Kaplan-Meier curves for overall survival, disease-free survival, and cancer-specific 562 
survival rates of 162 LADC patients according to the immunoreactivity of GAD1. P-563 
values were calculated using the log-rank test. Statistically significant P-values are in 564 
boldface type. 565 
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Supplementary Figure Legends 567 
 568 
Supplementary Figure S1. The average β-value (methylation level) of each CpG site 569 
targeted in the Infinium HumanMethylation450K data (Level 3) of 29 paired LADC 570 
tumor and non-tumorous tissue samples downloaded from TCGA Research Network 571 
(http://cancergenome.nih.gov). Data of some CpG sites were missing in the TCGA 572 
dataset. *P < 0.05 vs. paired non-tumorous tissues.  573 
 574 
Supplementary Figure S2. Kaplan-Meier overall survival curves of all selected 575 
datasets from KM plotter used in the present study (see Figure 2C). Hazard ratios (HR) 576 
and 95% confidence intervals in parentheses are shown for each dataset. P-values were 577 
calculated using the log-rank test. 578 
 579 
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